Orteronel-prednisone showed advantages over placebo-prednisone in PSA50 rate ( 25 % v 10 % , P < .001 ) and time to PSA progression ( median , 5.5 v 2.9 months , P < .001 ) but not pain response rate ( 12 % v 9 % ; P = .128 ) .